Agile pricing in response to rising procurement costs
First written in FY2023-Q1. 7 of 17 entries say "Advanced", first in FY2023-Q2. Latest entry: 2026-10-30.
0 other companies' latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「In terms of profitability, initiatives including improvements in the gross margins of long-tail products and imported products enabled the gross profit margin to remain broadly unchanged year on year at 30.2%, while gross profit exceeded the previous year’s level.」
Improved margins on long-tail products and imported products kept the gross profit margin broadly in line with the previous year at 30.2%. - FY2026-H1AdvancedAnnual report
「In terms of profitability, although the Medical segment weakened, the gross profit margin improved by 0.3 percentage points, driven by improvements in the gross margins of long-tail products and imported products.」
Despite weakness in the Medical segment, the gross profit margin improved by 0.3 percentage points year on year, owing mainly to improved margins on long-tail products and imported products. - FY2025AdvancedAnnual report
「In the second half, the gross profit margin improved by 0.1 percentage points year on year, owing to improved profitability of long-tail products and imported products and growth in the services business.」
In the second half, the gross profit margin improved by 0.1 percentage points year on year due to improved profitability of long-tail products and imported products and growth in the services business. - FY2025-H1Gross profit margin declined despite continued agile pricingAnnual report
「Regarding profitability, we have implemented agile pricing in parallel with higher procurement costs, but the gross profit margin declined by 1.1 percentage points year on year due in part to changes in the product mix in the Medical segment and an increase in inquiries for relatively high-priced equipment and instruments in the Lab and Industry segment.」
Continued agile pricing in response to higher procurement costs, but the gross profit margin declined by 1.1 percentage points year on year due in part to changes in the product mix and an increase in inquiries for high-priced equipment and instruments. - FY2024Full-year gross profit margin declined despite continued agile pricingAnnual report
「Regarding profitability, we have implemented agile pricing in parallel with higher procurement costs, but the gross profit margin declined by 0.5 percentage points year on year due in part to weak market conditions in the Medical segment following the reaction to the COVID-19 pandemic.」
Continued agile pricing in response to higher procurement costs, but the gross profit margin declined by 0.5 percentage points year on year due in part to weak market conditions in the Medical segment. - FY2024-Q3Gross profit margin declined despite continued agile pricingAnnual report
「Regarding profitability, we have implemented agile pricing in parallel with higher procurement costs, but the gross profit margin declined slightly year on year due in part to weak market conditions in the Medical segment following the reaction to the COVID-19 pandemic.」
Continued agile pricing in response to higher procurement costs, but the gross profit margin declined slightly year on year due in part to weak market conditions in the Medical segment following the reaction to the COVID-19 pandemic. - FY2024-Q2RestatedAnnual report
「Regarding profitability, we have implemented agile pricing in parallel with higher procurement costs, keeping the gross profit margin broadly at the same level as in the same quarter of the previous year.」
Continued agile pricing in response to higher procurement costs, maintaining the gross profit margin broadly at the same level as in the same quarter of the previous year. - FY2024-Q1RestatedAnnual report
「Regarding profitability, we have implemented agile pricing in parallel with higher procurement costs, and the gross profit margin has remained at the same level as in the same quarter of the previous year.」
Continued agile pricing in response to higher procurement costs, with the gross profit margin remaining at the same level as in the same quarter of the previous year. - FY2023AdvancedAnnual report
「We will also pursue data-driven, agile and optimal pricing, procurement at optimal lot sizes, and cost optimization taking procurement freight costs and other factors into account. In addition, we will seek to improve the gross profit margin through cost improvements for original products and expansion of our higher-value-added proprietary services business.」
Specified agile pricing as part of an integrated profitability improvement program encompassing cost optimization, including optimal lot-size procurement and freight costs, cost improvements for original products, and expansion of proprietary services. - FY2023-Q3AdvancedAnnual report
「We have continued to respond flexibly to higher procurement costs through our own efforts as described above, and the overall impact has remained limited.」
Continued measures including flexible pricing in response to higher procurement costs, with the overall impact remaining limited. - FY2023-Q2AdvancedAnnual report
「We have implemented flexible pricing in response to higher procurement prices in the supply chain. Demand for infection-control products such as medical gowns and aprons also increased during the seventh wave of COVID-19, when the number of positive cases reached a record level, contributing to higher sales.」
Implemented flexible pricing in response to higher procurement prices, keeping the overall impact of higher procurement costs limited. - FY2023-Q1First statedAnnual report
「In response to higher procurement costs, we have also been implementing agile pricing, and the overall impact has remained limited.」
First identified agile pricing as a separate initiative to address higher procurement costs.